StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a report published on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
Shares of NBRV opened at $0.00 on Friday. The firm has a market cap of $6,403.00, a price-to-earnings ratio of 0.00 and a beta of 1.53. Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12.
About Nabriva Therapeutics
See Also
- Five stocks we like better than Nabriva Therapeutics
- Dividend Payout Ratio Calculator
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- Investing in Travel Stocks Benefits
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.